Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control.

Ito H, Araki R, Matsumoto S, Izutsu T, Kusano E, Kondo J, Inoue H, Antoku S, Yamasaki T, Mori T, Togane M

Diabetology international29 Apr 2021

PMID35059245PMCIDPMC8733088DOI10.1007/s13340-021-00508-3PepBankPUB-35059245

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyEfficacy outcome
In patients with diabetes, additional dulaglutide therapy was associated with a significant HbA1c decrease.
In plain wordsIn patients with diabetes, adding dulaglutide was linked to lower HbA1c than at baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c with additional therapy
Study
n = 35
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weeklyAs given in this study (human).
Measurements
HbA1c change from baseline
−1.4%
additional therapy group (± 1.6)
Source sentences
Summary
The HbA1c values significantly decreased after the initiation of dulaglutide in all groups (additional therapy group, - 1.4 ± 1.6%; DPP-4 inhibitors group, - 1.2 ± 1.3%; and daily GLP-1 RAs group, - 0.5 ± 0.7%).
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly) were investigated.
Summary · context
The subjects were divided into the three groups based on the form in which therapy was started: additional therapy (n = 35), switched from dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 32) and switched from daily glucagon-like peptide-1 receptor agonists (GLP-1 RAs, n = 30).
Report a problemFND-3505924501
02HumanObservational studyEfficacy outcome
In patients with diabetes, switching from DPP-4 inhibitors to dulaglutide was associated with a significant HbA1c decrease.
In plain wordsSwitching from DPP-4 inhibitors to dulaglutide was linked to lower HbA1c than at baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c after DPP-4 inhibitor switch
Study
n = 32
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weeklyAs given in this study (human).
Measurements
HbA1c change from baseline
−1.2%
DPP-4 inhibitors group (± 1.3)
Source sentences
Summary
The HbA1c values significantly decreased after the initiation of dulaglutide in all groups (additional therapy group, - 1.4 ± 1.6%; DPP-4 inhibitors group, - 1.2 ± 1.3%; and daily GLP-1 RAs group, - 0.5 ± 0.7%).
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly) were investigated.
Summary · context
The subjects were divided into the three groups based on the form in which therapy was started: additional therapy (n = 35), switched from dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 32) and switched from daily glucagon-like peptide-1 receptor agonists (GLP-1 RAs, n = 30).
Report a problemFND-3505924502
03HumanObservational studyEfficacy outcome
In patients with diabetes, switching from daily GLP-1 receptor agonists to dulaglutide was associated with a significant HbA1c decrease.
In plain wordsSwitching from daily GLP-1 medicines to dulaglutide was linked to lower HbA1c than at baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c after daily GLP-1 agonist switch
Study
n = 30
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weeklyAs given in this study (human).
Measurements
HbA1c change from baseline
−0.5%
daily GLP-1 RAs group (± 0.7)
Source sentences
Summary
The HbA1c values significantly decreased after the initiation of dulaglutide in all groups (additional therapy group, - 1.4 ± 1.6%; DPP-4 inhibitors group, - 1.2 ± 1.3%; and daily GLP-1 RAs group, - 0.5 ± 0.7%).
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly) were investigated.
Summary · context
The subjects were divided into the three groups based on the form in which therapy was started: additional therapy (n = 35), switched from dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 32) and switched from daily glucagon-like peptide-1 receptor agonists (GLP-1 RAs, n = 30).
Report a problemFND-3505924503

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
After switching to dulaglutide, forty-six percent of daily GLP-1 agonist users reported fewer forgotten injections.
In plain wordsAfter switching to dulaglutide, some patients reported fewer forgotten injections than during daily GLP-1 treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseForgotten injections
Study
n = 30
Comparator
Prior daily GLP-1 receptor agonist therapy
Outcome group
Treatment adherence and retention · Whole body
Measurements
Subjects reporting fewer forgotten injections
46%
daily GLP-1 RAs group
Source sentences
Summary
Forty-six percent of the subjects in the daily GLP-1 RAs group reported that the incidence of forgetting injections of GLP-1 RA was decreased.
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly) were investigated.
Summary · context
The subjects were divided into the three groups based on the form in which therapy was started: additional therapy (n = 35), switched from dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 32) and switched from daily glucagon-like peptide-1 receptor agonists (GLP-1 RAs, n = 30).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3505924504
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Among patients switched from daily GLP-1 receptor agonists to dulaglutide, those who reported fewer forgotten injections had a larger HbA1c reduction than those with no change.
In plain wordsIn people who switched to dulaglutide, those who forgot fewer injections had larger HbA1c drops than those with no change in forgetting.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction by adherence improvement
Study
n: not reported in source
Comparator
Patients without a change in forgotten injections
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c reduction
0.9%
fewer forgotten injections group (± 0.9)
HbA1c reduction
0.1%
no change in forgotten injections group (± 0.4)
Source sentences
Summary
The reduction of HbA1c was significantly greater in the subjects who reported a decrease in the incidence of forgetting injections (0.9 ± 0.9%) in comparison to those in which there was no change (0.1 ± 0.4%).
2 context sentences(design, population, supporting numbers)
Summary · context
In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly) were investigated.
Summary · context
The subjects were divided into the three groups based on the form in which therapy was started: additional therapy (n = 35), switched from dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 32) and switched from daily glucagon-like peptide-1 receptor agonists (GLP-1 RAs, n = 30).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3505924505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.